Pulse Biosciences Inc PLSE.OQ PLSE.O is expected to report resultson August 12 for the period ending June 30 2025
LSEG's mean analyst estimate for Pulse Biosciences Inc is for a loss of 26 cents per share.
The one available analyst rating on the shares is "strong buy".
The average consensus recommendation for the advanced medical equipment & technology peer group is also "Strong Buy".
Wall Street's median 12-month price target for Pulse Biosciences Inc is $22.00, about 33.1% above its last closing price of $14.71
This summary was machine generated August 8 at 23:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)